Company Overview
DiaMedica Therapeutics Inc. operates as a clinical stage biopharmaceutical company dedicated to improving the lives of individuals suffering from severe ischemic diseases through the development of advanced therapeutic candidates. The firm functions within the healthcare sector and specifically the biotechnology industry, positioning itself to leverage high-growth potential in the treatment of ischemic conditions. The company maintains a market capitalization of $357.25M and employs 27 individuals to execute its research and development objectives. While the annual revenue is not reported in the available financial data, the current market cap of $357.25M suggests that the market values the company's intellectual property and pipeline potential, particularly regarding its lead candidate DM199, at a level that reflects significant early-stage risk and opportunity.
Financial Health
The company reports Net Income (TTM) of $-31,926,000 and EBITDA of $-33,560,000, with Revenue (TTM) listed as N/A, indicating that the firm is in a stage where expenses significantly outweigh current income generation. The gap between the reported Net Income of $-31,926,000 and the EBITDA of $-33,560,000 reveals a cost structure where interest and tax expenses account for approximately $2 million of the total loss, highlighting the heavy burden of interest obligations on the operating entity. Free Cash Flow stands at $-17,127,876, which indicates that the company is consuming substantial cash reserves to fund its clinical trials and operational costs rather than generating liquidity for shareholders. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure typical for early-stage biotechnology firms that have not yet achieved commercial product sales or profitability. The balance sheet shows Cash of $55.32M against Debt of $266,000, resulting in a Debt to Equity ratio of 0.52, which suggests a balance sheet that is highly leveraged relative to equity but carries minimal absolute debt obligations. Furthermore, the Current Ratio is 10.67, a metric that indicates an extremely strong short-term liquidity position where current assets vastly exceed current liabilities, providing ample buffer for immediate operational needs. Return on Equity is -64.1% and Return on Assets is -38.3%, metrics that reveal that management is currently generating negative returns on the capital base invested by shareholders and creditors as the company burns cash to advance its pipeline.
Valuation Assessment
The P/E Ratio (TTM) is N/A and the Forward P/E is -9.07, implying that the difference between these metrics is driven by the company's current lack of profitability and the negative earnings expectation embedded in the forward multiple. The Price to Book ratio is 6.92, which indicates that the market is valuing the company at a significant premium over its book value, a common characteristic for biotechnology firms where intangible assets and pipeline potential are not fully captured on the balance sheet. The Price to Sales ratio is N/A and the EV/EBITDA is -9.01, suggesting that traditional sales-based or earnings-based valuation multiples are not applicable in the conventional sense due to the absence of revenue and negative earnings. The 52-week high is $10.42 and the 52-week low is $3.19, meaning the stock price is currently trading within a range that reflects high volatility and uncertainty regarding the company's clinical outcomes. The Beta value is 1.10, which means the stock exhibits higher price volatility relative to the broader market, moving more aggressively than the market average during periods of financial stress or rally.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, indicating that historical growth rates cannot be calculated due to the company's short reporting history or lack of prior comparable periods. Since earnings growth data is unavailable, it is impossible to determine if earnings are growing faster or slower than revenue, as both metrics currently lack a year-over-year comparative baseline. As a non-dividend payer, the company has a Dividend Yield of N/A and a Payout Ratio of 0.0%, reflecting a strategy where the company reinvests all available cash flow and raises capital into research and development rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of current profitability or dividend income, relying entirely on future clinical success of candidates like DM199 to transition into a revenue-generating and income-distributing phase in the future.